Your browser doesn't support javascript.
loading
Nonresponder Considerations for Romosozumab Treatment.
Tominaga, Ayako; Wada, Keiji; Okazaki, Ken; Nishi, Hideharu; Terayama, Yasushi; Shimamoto, Shuji; Kodama, Yasuteru; Kato, Yoshiharu.
Afiliação
  • Tominaga A; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan. tominaga.ayako@twmu.ac.jp.
  • Wada K; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Okazaki K; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Nishi H; Hasuda Hospital, Saitama, Japan.
  • Terayama Y; Hasuda Hospital, Saitama, Japan.
  • Shimamoto S; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Kodama Y; Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Kato Y; Kita Shinagawa 3rd Hospital, Tokyo, Japan.
Calcif Tissue Int ; 113(2): 157-165, 2023 08.
Article em En | MEDLINE | ID: mdl-37138124
Romosozumab can increase bone mineral density (BMD) in patients with osteoporosis, but some patients do not respond to it. This study aimed to identify risk factors for being a nonresponder to romosozumab treatment. This retrospective observational study included 92 patients. Romosozumab (210 mg) was subcutaneously administered to the participants every 4 weeks over 12 months. We excluded patients who previously underwent treatment for osteoporosis to assess the impact of romosozumab alone. We evaluated the proportion of patients who did not respond to romosozumab treatment to the lumbar spine and hip with increased BMD. Nonresponders were defined as those with a bone density change of < 3% after 12 months of treatment. We compared demographics and biochemical markers between responders and nonresponders. We found that 11.5% of patients were nonresponders at the lumbar spine, and 56.8% were nonresponders at the hip. A risk factor for nonresponse at the spine was low type I procollagen N-terminal propeptide (P1NP) values at 1 month. The cutoff value for P1NP at month 1 was 50 ng/ml. We found that 11.5% and 56.8% of patients experienced no significant improvement in the lumbar spine and hip BMD, respectively. Clinicians should use nonresponse risk factors to inform decisions about romosozumab treatment for patients with osteoporosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose / Osteoporose Pós-Menopausa / Conservadores da Densidade Óssea Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Calcif Tissue Int Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose / Osteoporose Pós-Menopausa / Conservadores da Densidade Óssea Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Calcif Tissue Int Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão